Genome editing and metabolic engineering of alkaloid biosynthesis in plants (GEMPlant)

Description of the granted funding

In the current study, our aim is, for the first time, to apply CRISPR/Cas9 genome editing technology together with recently developed synthetic expression system (SES) for the regulation of alkaloid biosynthesis in plant sources, with the aim of establishment of biotechnological production system for target compounds scopolamine and anatabine. Scopolamine is a high-value anti-cholinergic drug which is currently extracted from cultivated plants. Anatabine, on the other hand is a novel drug lead currently actively investigated for various targets, e.g. neurological disorders. In this research, the aim is to use plant cell culture systems in an efficient and sustainable manner to provide high-value natural compounds. The knowhow created within this research will provide completely new concepts within plant metabolic engineering in diverse applications.
Show more

Starting year

2020

End year

2025

Granted funding

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

330128

Fields of science

Industrial biotechnology

Research fields

Teollinen biotekniikka

Identified topics

molecular biology, biochemistry